Home > Compound List > Product Information
Glycodiazine_Molecular_structure_CAS_339-44-6)
Click picture or here to close

Glycodiazine

Catalog No. DB01382 Name DrugBank
CAS Number 339-44-6 Website http://www.ualberta.ca/
M. F. C13H15N3O4S Telephone (780) 492-3111
M. W. 309.3409 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 1199

SYNONYMS

IUPAC name
N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide
IUPAC Traditional name
glycodiazine
Synonyms
Glymidine
Glidiazine

DATABASE IDS

CAS Number 339-44-6
PubChem CID 9565
PubChem SID 46507076

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
Indication Glycodiazine is used concomitantly with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
Pharmacology Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
Toxicity Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.
Affected Organisms
Humans and other mammals
Absorption Rapidly and completely absorbed following oral administration.
Half Life 4 hours.
Protein Binding 90% bound to plasma proteins.

REFERENCES